


PRODUCT INFORMATION



VEGFR Tyrosine Kinase Inhibitor II

Item No. 17654

CAS Registry No.: 269390-69-4
Formal Name: N-(4-chlorophenyl)-2-[(4-pyridinylmethyl)amino]-benzamide
Synonym: Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor II
MF: C₁₉H₁₆ClN₃O
FW: 337.8
Purity: ≥98%
UV/Vis.: λ_{max}: 220, 260, 345 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

VEGFR tyrosine kinase inhibitor II is supplied as a crystalline solid. A stock solution may be made by dissolving the VEGFR tyrosine kinase inhibitor II in the solvent of choice, which should be purged with an inert gas. VEGFR tyrosine kinase inhibitor II is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of VEGFR tyrosine kinase inhibitor II in ethanol is approximately 25 mg/ml and approximately 50 mg/ml in DMSO and DMF.

VEGFR tyrosine kinase inhibitor II is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, VEGFR tyrosine kinase inhibitor II should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. VEGFR tyrosine kinase inhibitor II has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

VEGFR tyrosine kinase inhibitor II is a pyridinyl-anthranilamide compound that inhibits the kinase activities of VEGFR2 (KDR), VEGFR1 (FLT1), and c-Kit (IC₅₀s = 20, 180, and 240 nM, respectively).¹ It displays minimal activity against c-Src and EGFR (IC₅₀s = 7 and 7.3 μM, respectively) and is inactive against Cdk1, c-Met, IGF-1R, and PKA (IC₅₀s > 10 μM).¹ VEGFR tyrosine kinase inhibitor II has been investigated for its potential to inhibit tumor induced angiogenesis.¹

Reference

1. Furet, P., Bold, G., Hofmann, F., *et al.* Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. *Bioorg. Med. Chem. Lett.* **13**(18), 2967-2971 (2003).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/16/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM